Parschauer Karah Herdman — SEC Form 4 filings
SEC reporting owner CIK 1677455. 18 Form 4 filings on record with FilingPulse; latest filed 2026-08-04.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-02-02 to 2026-08-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 11 filings — 78,127 shares, $2,200,689 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: sale of 12,846 shares @ $42.10 ($540,817) in Ultragenyx Pharmaceutical Inc., filed 2025-03-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | EVP and Chief Legal Officer | 10 | — | 11 legs · 53,308 sh · $1,876,490 | 9 |
| Evolus, Inc. (EOLS) | Director | 5 | — | 2 legs · 24,819 sh · $324,198 | 5 |
| Tenaya Therapeutics, Inc. (TNYA) | Director | 3 | — | — | 3 |
Form 4 filings — Parschauer Karah Herdman
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-04 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 1,900 @ $24.92 | EDGAR |
| 2026-06-15 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 1,899 @ $24.62 | EDGAR |
| 2026-05-29 | 4 | Tenaya Therapeutics, Inc. (TNYA) | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 28,895 @ $0 · Grant/award (A): 49,960 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 6,018 @ $21.40 · Sale (S): 3,508 @ $22.67 | EDGAR |
| 2026-03-03 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 11,137 @ $0 · Sale (S): 8,135 @ $22.80 | EDGAR |
| 2026-02-19 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 45,559 @ $0 | EDGAR |
| 2025-09-12 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 2,450 @ $31.17 | EDGAR |
| 2025-05-30 | 4 | Tenaya Therapeutics, Inc. (TNYA) | Grant/award (A): 107,400 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | Evolus, Inc. (EOLS) | Sale (S): 12,888 @ $12.99 | EDGAR |
| 2025-03-11 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 7,364 @ $0 · Grant/award (A): 11,146 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 18,443 @ $0 · Sale (S): 12,846 @ $42.10 | EDGAR |
| 2025-03-03 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 2,230 @ $42.93 · Sale (S): 760 @ $42.75 · Grant/award (A): 14,494 @ $0 · Grant/award (A): 26,074 (derivative) @ $0 | EDGAR |
| 2024-10-21 | 4 | Tenaya Therapeutics, Inc. (TNYA) | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Sale (S): 9,806 @ $45 | EDGAR |
| 2024-03-05 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 17,800 @ $0 · Grant/award (A): 957 @ $0 · Sale (S): 3,756 @ $53.76 · Grant/award (A): 31,400 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Evolus, Inc. (EOLS) | Grant/award (A): 6,464 @ $0 · Grant/award (A): 9,377 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Evolus, Inc. (EOLS) | Sale (S): 11,931 @ $13.14 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1677455 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →